Chronic myeloid lukemia cells: Tyrosine kinase inhibition using ag 957 and arachidonic acid inducing apoptosis

Abstract

Chronic myelogenous leukemia (CML) is characterized by Philadelphia chromosome that fuses genetic sequences of the BCR gene on chromosome 22. AG 957, a member of the tyrphostin compound produces a selective inhibition of P 210 BCR/ABL tyrosine phosphorylation. A group of ten patients with CML in chronic phase were treated after CD34 separation with 1 to 100 umol/L of AG 957. All patients were 100% Ph1 positive. Eight patients showed a b3a2 BCR/ABL junction and two cases showed a b2a2 junction when analyzed by RT-PCR. The effect of AG 957 on CML and normal CD34 cells in culture assay (CFU/MIX, BFU-E and CFU-GM) is clearly demonstrated. The inhibition on CML untreated and AG957 treated colonies was from 2%–7% for CFU-MIX, 38%–80% for BFU-E and 31%–18–% for CFU-GM. In the group of normal samples the inhibition ranged from 4%–8% for CFU-MIX, 24%–96% for BFU-E and 4%–64% for CFU-GM. The inhibitory effect of AG 957 on CML progenitors is statistically significant at the dose of 1 umol/L for CFU-MIX and BFU-E, 5 umol/L for CFU-GM. For colonies obtained from normal progenitors the inhibiting dose of AG 957 was more consistent: 5 umol/L for CFU-MIX and BFU-E, 10 umol/L for CFU-GM. These data demonstrated the possibility to select non clonal CML progenitors after incubation with the PTK inhibitor AG 957. This selection of “normal” progenitors from CML marrow could be used for autograft in patients without suitable allogeneic bone marrow donors. The research is in progression to explore the potential therapeutic effect of AG 957 in combination with other agents (IFN - ARA-C) and/or inductors of apoptosis as arachidonic acid in cell culture, to briefly translate the “in vitro” experimental approach to clinical therapeutic application.